Scancell Holdings PLC CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company’s latest interim results and its progress. He highlighted five key updates, including the latest data from the SCOPE study, which investigates the company’s cancer vaccine for melanoma. The interim results showed an 80% disease control rate and a 72% overall response rate, significantly outperforming current standard-of-care treatments. L’Huillier also discussed the strong recruitment progress in the SCOPE and ModiFY studies, as well as an additional licensing deal with Genmab, reinforcing industry validation of Scancell’s antibody portfolio. The company recently raised £11.3 million, securing funding to advance its clinical programs through 2025 and into the second half of 2026. He noted organizational changes, including his appointment as CEO and the hiring of Dr Nermeen Varawalla as chief medical officer, allowing Professor Lindy Durrant to refocus on scientific leadership as CSO. Looking ahead, Scancell expects multiple clinical data readouts in 2025, including full results from the SCIB1 arm of the SCOPE study by mid-year, as well as new data from the next-generation iSCIB1+ vaccine. Updates from the ModiFY study, including further efficacy results from the Modi-1 vaccine in head and neck cancer, are also anticipated in the second half of the year. L’Huillier expressed confidence in Scancell’s future, emphasising its strong clinical pipeline, robust team, and committed investor base. “We have the team and the resources to execute the plan, and we will do that.” For more updates on Scancell and its progress, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for more interviews. #Scancell #Biotech #CancerResearch #Immunotherapy #SCOPEStudy #ModiFYStudy #ClinicalTrials #HealthcareInnovation #Biopharma #Investing